In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency
Open Access
- 7 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e30792
Abstract
Recent findings suggest that the relaxin-3 neural network may represent a new ascending arousal pathway able to modulate a range of neural circuits including those affecting circadian rhythm and sleep/wake states, spatial and emotional memory, motivation and reward, the response to stress, and feeding and metabolism. Therefore, the relaxin-3 receptor (RXFP3) is a potential therapeutic target for the treatment of various CNS diseases. Here we describe a novel selective RXFP3 receptor positive allosteric modulator (PAM), 3-[3,5-Bis(trifluoromethyl)phenyl]-1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea (135PAM1). Calcium mobilization and cAMP accumulation assays in cell lines expressing the cloned human RXFP3 receptor show the compound does not directly activate RXFP3 receptor but increases functional responses to amidated relaxin-3 or R3/I5, a chimera of the INSL5 A chain and the Relaxin-3 B chain. 135PAM1 increases calcium mobilization in the presence of relaxin-3NH2 and R3/I5NH2 with pEC50 values of 6.54 (6.46 to 6.64) and 6.07 (5.94 to 6.20), respectively. In the cAMP accumulation assay, 135PAM1 inhibits the CRE response to forskolin with a pIC50 of 6.12 (5.98 to 6.27) in the presence of a probe (10 nM) concentration of relaxin-3NH2. 135PAM1 does not compete for binding with the orthosteric radioligand, [125I] R3I5 (amide), in membranes prepared from cells expressing the cloned human RXFP3 receptor. 135PAM1 is selective for RXFP3 over RXFP4, which also responds to relaxin-3. However, when using the free acid (native) form of relaxin-3 or R3/I5, 135PAM1 doesn't activate RXFP3 indicating that the compound's effect is probe dependent. Thus one can exchange the entire A-chain of the probe peptide while retaining PAM activity, but the state of the probe's c-terminus is crucial to allosteric activity of the PAM. These data demonstrate the existence of an allosteric site for modulation of this GPCR as well as the subtlety of changes in probe molecules that can affect allosteric modulation of RXFP3.Keywords
This publication has 48 references indexed in Scilit:
- Strategies for the identification of allosteric modulators of G-protein-coupled receptorsBiochemical Pharmacology, 2011
- Impact of species variability and ‘probe‐dependence’ on the detection andin vivovalidation of allosteric modulation at the M4muscarinic acetylcholine receptorBritish Journal of Pharmacology, 2010
- G protein coupled receptors as allosteric proteins and the role of allosteric modulatorsJournal of Receptors and Signal Transduction, 2010
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Relaxin family peptide receptors – from orphans to therapeutic targetsDrug Discovery Today, 2008
- The Relaxin Family Peptide Receptor 3 Activates Extracellular Signal-Regulated Kinase 1/2 through a Protein Kinase C-Dependent MechanismMolecular Pharmacology, 2007
- Small-molecule agonists for the glucagon-like peptide 1 receptorProceedings of the National Academy of Sciences, 2007
- Responses of GPCR135 to Human Gene 3 (H3) Relaxin in CHO‐K1 Cells Determined by MicrophysiometryAnnals of the New York Academy of Sciences, 2005
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Identification of a mouse orthologue of the G-protein-coupled receptor SALPR and its expression in adult mouse brain and during developmentDevelopmental Brain Research, 2004